Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Exchange Rate Effect (2021 - 2025)

Historic Exchange Rate Effect for Arrowhead Pharmaceuticals (ARWR) over the last 5 years, with Q4 2025 value amounting to $106000.0.

  • Arrowhead Pharmaceuticals' Exchange Rate Effect rose 25588.24% to $106000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$227000.0, marking a year-over-year decrease of 10557.6%. This contributed to the annual value of -$401000.0 for FY2025, which is 10955.44% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Exchange Rate Effect stood at $106000.0 for Q4 2025, which was up 25588.24% from -$24000.0 recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Exchange Rate Effect's 5-year high stood at $4.3 million during Q3 2024, with a 5-year trough of -$402000.0 in Q1 2025.
  • Moreover, its 5-year median value for Exchange Rate Effect was -$24000.0 (2025), whereas its average is $218411.8.
  • Examining YoY changes over the last 5 years, Arrowhead Pharmaceuticals' Exchange Rate Effect showed a top increase of 500000.0% in 2023 and a maximum decrease of 750000.0% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Exchange Rate Effect (Quarter) stood at -$39000.0 in 2021, then plummeted by 212.82% to -$122000.0 in 2022, then surged by 147.54% to $58000.0 in 2023, then tumbled by 217.24% to -$68000.0 in 2024, then soared by 255.88% to $106000.0 in 2025.
  • Its Exchange Rate Effect was $106000.0 in Q4 2025, compared to -$24000.0 in Q3 2025 and $93000.0 in Q2 2025.